Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | PDE6A | P16499 | 1/20 | 0.65 |
| ▸ | PDE6G | P18545 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE6B | P35913 | 1/20 | 0.65 |
| ▸ | PDE6C | P51160 | 1/20 | 0.65 |
| ▸ | PDE1A | P54750 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7721486 | 0.82 | PDE5A (0.64) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| Zaprinast SCHEMBL50328 | 0.82 | PDE5A (0.65) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL1962446 | 0.81 | PDE5A (1.00) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7027365 | 0.81 | PDE5A (0.49) | PDE5APDE6CPDE11A | |
| SCHEMBL7722659 | 0.81 | PDE5A (0.67) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7375297 | 0.80 | PDE5A (0.73) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7408452 | 0.80 | PDE5A (0.67) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL26362616 | 0.79 | PDE5A (0.45) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7722411 | 0.79 | PDE5A (0.77) | PDE5AKDM4EALDH1A1KMT2AMEN1 | |
| Zaprinast SCHEMBL30713719 | 0.79 | PDE5A (1.00) | PDE5AKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180078559-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY COPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-8329656-B2 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | SWITCH BIOTECH AG (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8278300-B2 | Use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8268785-B2 | Such as tadalafil or sildenafil; vitiligo; use in combination with Pimecrolimus, Tacrolimus, or Cyclosporin A | SWITCH BIOTECH AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20110142956-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | PEUKER HEIDEMARIE | 2011-06-16 | — | — | US | disclosed |
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| WO-2006018088-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | SWITCH BIOTECH AG (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | disclosed |
| US-6593332-B2 | Phosphodiesterase inhibitors; sexual disorders | PFIZER INC. | 2003-07-15 | — | — | US | disclosed |
| US-6586439-B2 | Therapy for sexual disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030013727-A1 | Pharmaceutically active compounds | MAW GRAHAM NIGEL (GB) | 2003-01-16 | — | — | US | disclosed |
| US-20030004173-A1 | Pharmaceutically active compounds | MAW GRAHAM NIGEL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-6440982-B1 | INHIBITORS OF CYCLIC GUANOSINE MONOPHOSPHATE DIESTERASES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1092718-A1 | 2-(2-Alkoxy-5-heterocyclylsulphonylphenyl)purin-6-ones as phosphodiesterase inhibitors | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004173-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885KDM4E 3234/4885ALDH1A1 439/4885 |
| US-20110142956-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | PDE5A, PDE12, PDE2A | PDE5A 1/4885KDM4E 618/4885ALDH1A1 342/4885 |
| US-20030013727-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885KDM4E 3234/4885ALDH1A1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.